This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
The largest U.S. health insurer UnitedHealth Group (UNH - Free Report) reported robust second-quarter 2018 results. The company breezed past the Zacks Consensus Estimate on earnings but revenues came on par. The company raised its full-year earnings outlook encouraged by strong growth in its health-care plan membership and premiums. Earnings per share came in at $3.14, well above the Zacks Consensus Estimate of $3.
VHT IYH IHF UNH IEHS
The Q2 earnings season has commenced and Johnson & Johnson (JNJ - Free Report) was the first drug company to report on Jul 17, before the opening bell. The world's biggest maker of health care products continued its long streak of earnings beat and outpaced the estimate on the revenue front. However, it trimmed its outlook for 2018. Earnings per share came in at $2.10, four cents ahead of the Zacks Consensus Estimate and 14.
VHT IEIH IYH JNJ IHE
Traditional portfolio strategies for hedging against inflation can be effective during quickly rising or higher than expected inflation, but often provide lackluster or inconsistent returns during periods of low inflation.
BKLN VFH IYF VTIP TIP GLD EV IAU VGT VHT O87 IBB STIP ROBO
Analysts expect Merck & Co.’s (MRK) revenues to increase ~7.1% to $10.1 billion in 1Q18, compared to revenues of $9.4 billion in 1Q17. Revenues for 1Q18 are expected to have a positive impact on growth in operating revenues and a favorable impact from foreign exchange.
With just a day away to the month of May, investors have turned cautious given that seasonality will play a huge role in pushing stocks down for the next six months, as per the old adage “Sell in May and Go Away.” According to this investment saying, the stock market has a long history of weak performance during the summer months (May to October). Will May 2018 Pen the Same Story? After a blockbuster start, the U.
NOBL VIG VHT VTV USLB DEF VDC USMV SCHV SPLV PWV
Healthcare space has been on a tough journey this year. The popular ETF like Health Care Select Sector SPDR Fund (XLV - Free Report) has shed 0.4% so farwhile Vanguard Health Care ETF (VHT - Free Report) and Fidelity MSCI Health Care Index ETF (FHLC - Free Report) have gained at least 0.8%. Meanwhile, iShares U.S. Healthcare ETF (IYH - Free Report) has added 0.1%. The mixed trend is likely to continue heading into the Q1 earnings season as some big names like Pfizer (PFE - Free Report) , Merck (MRK - Free Report) , Amgen (AMGN - Free Report) , AbbVie (ABBV - Free Report) , Gilead Sciences (GILD - Free Report) and Bristol-Myers Squibb (BMY - Free Report) are lined up to report this week and in the next.
VHT AMGN IYH FHLC GILD ABBV PFE ABBV
The PowerShares S&P SmallCap Health Care Portfolio (PSCH - Free Report) was launched on 04/07/2010, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Broad segment of the U.S. equity market.
VHT IART HAE CHE
When it comes to assessing the cost of a retirement mutual fund or exchange-traded fund, most investors simply look at the absolute value of the expense ratio. The lower the expense ratio, they figure, the better. That’s not always true. For some ETFs and funds, the definition of low-cost retirement funds is relative.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET